Ensign Peak Advisors
ELDN icon

Ensign Peak Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

Ensign Peak Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.28M Sell
2,101,224
-363,695
-15% -$1.32M 0.01% 470
2026
Q1 		$7.59M Hold
2,464,919
– – 0.01% 459
2025
Q4 		$3.72M Buy
2,464,919
+1,200,000
+95% +$2.85M 0.01% 573
2025
Q3 		$3.28M Hold
1,264,919
– – 0.01% 683
2025
Q2 		$3.43M Hold
1,264,919
– – 0.01% 730
2025
Q1 		$4.29M Hold
1,264,919
– – 0.01% 668
2024
Q4 		$5.21M Buy
1,264,919
+821,918
+186% +$3.24M 0.01% 636
2024
Q3 		$1.1M Hold
443,001
– – ﹤0.01% 1260
2024
Q2 		$1.17M Hold
443,001
– – ﹤0.01% 1185
2024
Q1 		$913K Hold
443,001
– – ﹤0.01% 1388
2023
Q4 		$797K Hold
443,001
– – ﹤0.01% 1506
2023
Q3 		$607K Hold
443,001
– – ﹤0.01% 1525
2023
Q2 		$607K Hold
443,001
– – ﹤0.01% 1570
2023
Q1 		$1.05M Hold
443,001
– – ﹤0.01% 1199
2022
Q4 		$1.03M Buy
443,001
+355,715
+408% +$879K ﹤0.01% 1134
2022
Q3 		$241K Buy
87,286
+10,186
+13% +$32.4K ﹤0.01% 1796
2022
Q2 		$188K Hold
77,100
– – ﹤0.01% 1812
2022
Q1 		$304K Hold
77,100
– – ﹤0.01% 1748
2021
Q4 		$340K Buy
77,100
+69,872
+967% +$353K ﹤0.01% 1770
2021
Q3 		$45K Sell
7,228
-28,883
-80% -$202K ﹤0.01% 1836
2021
Q2 		$286K Hold
36,111
– – ﹤0.01% 1683
2021
Q1 		$386K Hold
36,111
– – ﹤0.01% 1637
2020
Q4 		$556K Hold
36,111
– – ﹤0.01% 1581
2020
Q3 		$618K Buy
+36,111
New +$356K ﹤0.01% 1475

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Ensign Peak Advisors's ELDN Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Eledon Pharmaceuticals (ELDN) stake by 15% in Q2 2026, selling an estimated $1.32M and leaving 2,101,224 shares worth $8.28M. The position accounts for 0.01% of the portfolio, ranked #470.

Ensign Peak Advisors first reported a position in ELDN in Q3 2020 and has held it in 24 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Ensign Peak Advisors held 2,101,224 shares of Eledon Pharmaceuticals worth $8.28M as of Q2 2026.
  • Ensign Peak Advisors sold 363,695 Eledon Pharmaceuticals shares in Q2 2026, an estimated $1.32M.
  • Eledon Pharmaceuticals made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #470 holding.
  • Ensign Peak Advisors first reported a position in Eledon Pharmaceuticals in Q3 2020 and has held it in 24 quarters since.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.